Potential roles of cellular proteins in HIV-1

Reviews in Medical Virology

Volumn 12, Issue 6, 2002, Pages 359-374

  Ott, David E ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; AMINO ACID TRANSFER RNA LIGASE; CELL PROTEIN; CHAPERONE; CYCLOPHILIN A; HLA ANTIGEN CLASS 2; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; UBIQUITIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LIFE CYCLE; PROTEIN FUNCTION; REVIEW; VACCINATION; VIRION; VIRUS CELL INTERACTION;

ANTIGENS, SURFACE; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE PROTEINS; PROTEINS; VIRION;

EID: 0036845721     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.367     Document Type: Review

References (89)

1. Shearer GM. HIV-induced immunopathogenesis. Immunity 1998; 9: 587-593.
2. Coffin J, Hughes S, Varmus H. Retroviruses. Cold Spring Harbor Press: Plainview, NY, 1997.
3. Burmeister T. Oncogenic retroviruses in animals and humans. Rev Med Virol 2001; 11: 369-380.
4. Ott DE. Cellular proteins in HIV. Rev Med Virol 1997; 7: 167-180.
5. Ott DE, Coren LV, Johnson DG, et al. Actin-binding cellular proteins inside human immunodeficiency virus type 1. Virology 2000; 266: 42-51.
6. Ott DE, Coren LV, Johnson DG, Sowder RC, II, Arthur LO, Henderson LE. Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain. AIDS Res Hum Retroviruses 1995; 11: 1003-1006.
7. Ott DE, Coren LV, Kane BP, et al. Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. J Virol 1996; 70: 7734-7743.
8. Tremblay MJ, Fortin JF, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1998; 19: 346-351.
9. Bastiani L, Laal S, Kim M, Zolla-Pazner S. Host cell- dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol 1997; 71: 3444-3450.
10. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science 1995; 267: 483-489.
11. Zavada J. The pseudotypic paradox. J Gen Virol 1982; 63: 15-24.
12. Hammarstedt M, Wallengren K, Pedersen KW, Roos N, Garoff H. Minimal exclusion of plasma membrane proteins during retroviral envelope formation. Proc Natl Acad Sci USA 2000; 97: 7527-7532.
13. Nguyen DH, Hildreth JE. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000; 74: 3264-3272.
14. Esser MT, Graham DR, Coren LV, et al. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: Implications for viral pathogenesis and immune regulation. J Virol 2001; 75: 6173-6182.
15. Lallos LB, Laal S, Hoxie JA, Zolla-Pazner S, Bandres JC. Exclusion of HIV coreceptors CXCR4, CCR5, and CCR3 from the HIV envelope. AIDS Res Hum Retroviruses 1999; 15: 895-897.
16. Sparacio S, Pfeiffer T, Holtkotte D, Bosch V. Interretroviral fusion mediated by human immunodeficiency virus or murine leukemia virus glycoproteins: Independence of cellular membranes and membrane vesicles. Virology 2002; 294: 305-311.
17. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001 98: 13925-13930.
18. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 31-39.
19. Cantin R, Martin G, Tremblay MJ. A novel virus capture assay reveals a differential acquisition of host HLA-DR by clinical isolates of human immunodeficiency virus type 1 expanded in primary human cells depending on the nature of producing cells and the donor source. J Gen Virol 2001; 82: 2979-2987.
20. Poon DT, Coren LV, Ott DE. Efficient incorporation of HLA class II onto human immunodeficiency virus type 1 requires envelope glycoprotein packaging. J Virol 2000; 74: 3918-3923.
21. Arthur LO, Bess JW, Jr, Sowder RC, II, et al. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science 1992; 258: 1935-1938.
22. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: A review. Crit Rev Immunol 1998; 18: 389-418.
23. Rossio JL, Bess JW, Jr, Henderson LE, Cresswell P, Arthur LO. HLA class II on HIV-1 particles is functional in superantigen presentation to human T cells: Implications for HIV pathogenesis. AIDS Res Hum Retroviruses 1995; 11: 1433-1439.
24. Esser MT, Bess JW, Jr, Suryanarayana K, et al. Partial activation and induction of apoptosis in CD4(+) and CD8(+) T lymphocytes by conformationally authentic noninfectious human immunodeficiency virus type 1. J Virol 2001; 75: 1152-1164.
25. Paquette JS, Fortin JF, Blanchard L, Tremblay MJ. Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity. J Virol 1998; 72: 9329-9336.
26. Fortin J-F, Cantin R, Lamontagne G, Tremblay M. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997; 71: 3588-3596.
27. Fortin JF, Cantin R, Tremblay MJ. T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1. J Virol 1998; 72: 2105-2112.
28. Liao Z, Roos JW, Hildreth JE. Increased infectivity of HIV type 1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4. AIDS Res Hum Retroviruses 2000; 16: 355-366.
29. Olinger GG, Saifuddin M, Hart ML, Spear GT. Cellular factors influence the binding of HIV type 1 to cells. AIDS Res Hum Retroviruses 2002 18: 259-267.
30. Ugolini S, Mondor I, Sattentau QJ. HIV-1 attachment: Another look. Trends Microbiol 1999; 7: 144-149.
31. Fujiwara M, Tsunoda R, Shigeta S, Yokota T, Baba M. Human follicular dendritic cells remain uninfected and capture human immunodeficiency virus type 1 through CD54-CD11a interaction. J Virol 1999; 73: 3603-3607.
32. Hioe CE, Hildreth JE, Zolla-Pazner S. Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1. AIDS Res Hum Retroviruses 1999; 15: 523-531.
33. Fortin JF, Cantin R, Bergeron MG, Tremblay MJ. Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization. Virology 2000; 268: 493-503.
34. Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidy-linositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 1997; 78: 1907-1911.
35. Lawn SD, Roberts BD, Griffin GE, Folks TM, Butera ST. Cellular compartments of human immunodeficiency virus type 1 replication in vivo: Determination by presence of virion-associated host proteins and impact of opportunistic infection. J Virol 2000; 74: 139-145.
36. Bestman-Smith J, Desormeaux A, Tremblay MJ, Bergeron MG. Targeting cell-free HIV and virally-infected cells with anti-HLA-DR immunoliposomes containing amphotericin B. AIDS 2000; 14: 2457- 2465.
37. Saifuddin M, Crnich C, Long T, Saarloos MN, Spear GT. Transfer of host T-cell membrane HLA-DR and CD25 to target cells by human retroviruses. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 196-202.
38. lbarrondo FJ, Choi R, Geng YZ, et al. HIV type 1 Gag and nucleocapsid proteins: Cytoskeletal localization and effects on cell motility. AIDS Res Hum Retroviruses 2001; 17: 1489-1500.
39. Liu B, Dai R, Tian CJ, Dawson L, Gorelick R, Yu XF. Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin. J Virol 1999; 73: 2901-2908.
40. Wilk T, Gowen B, Fuller SD. Actin associates with the nucleocapsid domain of the human immunodeficiency virus gag polyprotein. J Virol 1999; 73: 1931-1940.
41. Welker R, Hohenberg H, Tessmer U, Huckhagel C, Krausslich HG. Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J Virol 2000; 74: 1168-1177.
42. Nermut MV, Wallengren K, Pager J. Localization of actin in Moloney murine leukemia virus by immunoelectron microscopy. Virology 1999; 260: 23-34.
43. Cimarelli A, Luban J. Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol 1999; 73: 5388-5401.
44. Kinzy T, Goldman E. Nontranslational functions of components of the translational apparatus. In Translational Control, Sonenberg N, Hershey JWB, Mathews MB (eds). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2000; 973-997.
45. Maniatis T, Reed R. An extensive network of coupling among gene expression machines. Nature 2002; 416(6880): 499-506.
46. Butsch M, Boris-Lawrie K. Destiny of unspliced retroviral RNA: Ribosome and/or virion? J Virol 2002; 76: 3089-3094.
47. Poon DT, Chertova EN, Ott DE. Human immunodeficiency virus type 1 preferentially encapsidates genomic RNAs that encode pr55(Gag): Functional linkage between translation and RNA packaging. Virology 2002; 293: 368-378.
48. Ross AF, Oleynikov Y, Kislauskis EH, Taneja KL, Singer RH. Characterization of a beta-actin mRNA zipcode-binding protein. Mol Cell Biol 1997; 17: 2158-2165.
49. Mouland AJ, Mercier J, Luo M, Bernier L, DesGroseillers L, Cohen EA. The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: Evidence for a role in genomic RNA encapsidation. J Virol 2000; 74: 5441-5451.
50. Bassell G, Singer RH. mRNA and cytoskeletal filaments. Curr Opin Cell Biol 1997; 9: 109-115.
51. Cen S, Khorchid A, Javanbakht H, et al. Incorporation of lysyl-tRNA synthetase into human immunodeficiency virus type 1. J Virol 2001; 75: 5043-5058.
52. Lama J, Trono D. Human immunodeficiency virus type 1 matrix protein interacts with cellular protein HO3. J Virol 1998; 72: 1671-1676.
53. Luban J. Absconding with the chaperone: Essential Cyclophilin-Gag interaction in HIV-1 virions. Cell 1996; 87: 1157-1159.
54. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997; 71: 5871-5877.
55. Wiegers K, Rutter G, Schubert U, Grattinger M, Krausslich HG. Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid. Virology 1999; 257: 261-274.
56. Grattinger M, Hohenberg H, Thomas D, Wilk T, Muller B, Krausslich HG. In vitro assembly properties of wild-type and cyclophilin-binding defective human immunodeficiency virus capsid proteins in the presence and absence of cyclophilin A. Virology 1999; 257: 247-260.
57. Saphire AC, Bobardt MD, Gallay PA. Trans-complementation rescue of cyclophilin A-deficient viruses reveals that the requirement for cyclophilin A in human immunodeficiency virus type 1 replication is independent of its isomerase activity. J Virol 2002; 76: 2255-2262.
58. Saphire AC, Bobardt MD, Gallay PA. Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. EMBO J 1999; 18: 6771-6785.
59. Pushkarsky T, Zybarth G, Dubrovsky L, et al. CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proc Natl Acad Sci USA 2001; 98: 6360-6365.
60. Saphire AC, Bobardt MD, Gallay PA. Cyclophilin A plays distinct roles in human immunodeficiency virus type 1 entry and postentry events, as revealed by spinoculation. J Virol 2002; 76: 4671-4677.
61. Zhang YJ, Hatziioannou T, Zang T, et al. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol 2002; 76: 6332-6343.
62. Gurer C, Cimarelli A, Luban J. Specific incorporation of heat shock protein 70 family members into primate lentiviral virions. J Virol 2002; 76: 4666-4670.
63. Ciechanover A. The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J 1998; 17: 7151-7160.
64. Wilkinson KD. Ubiquitination and deubiquitination: Targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000; 11: 141-148.
65. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2001; 2: 195-201.
66. Conaway RC, Brower CS, Conaway JW. Emerging roles of ubiquitin in transcription regulation. Science 2002; 296: 1254-1258.
67. Ott DE, Coren LV, Copeland TD, et al. Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type-1 and simian immunodeficiency virus and the pl2Gag protein of Moloney murine leukemia virus. J Virol 1998; 72: 2962-2968.
68. Ott DE, Coren LV, Chertova EN, Gagliardi TD, Schubert U. Ubiquitination of HIV-1 and MuLV Gag. Virology 2000; 278: 111-121.
69. Ott DE, Coren LV, Sowder IRC, Adams J, Nagashima K, Schubert U. Equine infectious anemia virus and the ubiquitin-proteasome system. J Virol 2002; 76: 3038-3044.
70. Strack B, Calistri A, Accola MA, Palu G, Gottlinger HG. A role for ubiquitin ligase recruitment in retrovirus release. Proc Natl Acad Sci USA 2000; 97(24): 13063-13068.
71. Freed EO. Viral late domains. J Virol 2002; 76: 4679-4687.
72. Gonen H, Smith CE, Siegel NR, et al. Protein synthesis elongation factor EF-1 alpha is essential for ubiquitin-dependent degradation of certain N alpha-acetylated proteins and may be substituted for by the bacterial elongation factor EF-Tu. Proc Natl Acad Sci USA 1994; 91: 7648-7652.
73. Gonen H, Dickman D, Schwartz AL, Ciechanover A. Protein synthesis elongation factor EF-1 alpha is an isopeptidase essential for ubiquitin-dependent degradation of certain proteolytic substrates. Adv Exp Med Biol 1996; 389: 209-219.
74. Schubert U, Ott DE, Chertova EN, et al. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci USA 2000; 97: 13057-13062.
75. Patnaik A, Chau V, Wills JW. Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci USA 2000; 97: 13069-13074.
76. Patnaik A, Chau V, Li F, Montelaro RC, Wills JW. Budding of equine infectious anemia virus is insensitive to proteasome inhibitors. J Virol 2002; 76(6): 2641-2647.
77. Demirov DG, Ono A, Orenstein JM, Freed EO. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci USA 2002; 99: 955-960.
78. VerPlank L, Bouamr F, LaGrassa TJ, et al. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55Gag. Proc Natl Acad Sci USA 2001; 98: 7724-7729.
79. Garrus JE, von Schwedler UK, Pornillos OW, et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001; 107: 55-65.
80. Carter CA. Tsg101: HIV-1's ticket to ride. Trends Microbiol 2002; 10: 203-205.
81. Cartier C, Deckert M, Grangeasse C, et al. Association of ERK2 mitogen-activated protein kinase with human immunodeficiency virus particles. J Virol 1997; 71: 4832-4837.
82. Yang X, Gabuzda D. Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway. J Virol 1999; 73: 3460-3466.
83. Jacque JM, Mann A, Enslen H, et al. Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase. EMBO J 1998; 17: 2607-2618.
84. Mueller RD, Yasuda H, Hatch CL, Bonner WM, Bradbury EM. Identification of ubiquitinated histones 2A and 2b in Physarum polycephalum. J Biol Chem 1985; 260: 5147-5153.
85. Davis DA, Newcomb FM, Starke DW, Ott DE, Mieyal JJ, Yarchoan R. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. J Biol Chem 1997; 272: 25935-25940.
86. Gupta K, Ott D, Hope TJ, Siliciano RF, Boeke JD. A human nuclear shuttling protein that interacts with human immunodeficiency virus type 1 matrix is packaged into virions. J Virol 2000; 74: 11811-11824.
87. Yung E, Sorin M, Pal A, et al. Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nat Med 2001; 7: 920-926.
88. Briggs CJ, Ott DE, Coren LV, Oroszlan S, Tozser J. Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Arch Virol 1999; 144: 2151-2160.
89. Mansky LM, Preveral S, Selig L, Benarous R, Benichou S. The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate. J Virol 2000; 74: 7039-7047.